Investment Rating - The investment rating for the company is maintained at "Buy-A" with a target price of 68.81 CNY per share over the next six months [5]. Core Insights - The company reported a revenue of 31.629 billion CNY for 2025, representing a year-on-year growth of 13.02%. The net profit attributable to shareholders was 7.711 billion CNY, up 21.69% year-on-year [1]. - The innovative drug cluster has entered the sales realization phase, with sales revenue from innovative drugs reaching 16.342 billion CNY, a growth of 26.09% year-on-year, accounting for 58.34% of total drug sales [1]. - The company has approximately 26 innovative drugs approved for market, with 9 new drugs expected to drive growth in 2026 [1]. - The company generated 3.392 billion CNY from licensing agreements, which has become a significant part of its revenue stream [2]. Financial Projections - Revenue projections for 2026 to 2028 are 35.956 billion CNY, 41.112 billion CNY, and 47.616 billion CNY respectively, with net profits of 9.134 billion CNY, 10.437 billion CNY, and 12.250 billion CNY [3][8]. - The expected earnings per share (EPS) for 2026, 2027, and 2028 are 1.38 CNY, 1.57 CNY, and 1.85 CNY respectively, with corresponding price-to-earnings (PE) ratios of 40.1, 35.1, and 29.9 [3][8].

Investment Rating - The report maintains a neutral rating for the company, 恒瑞医药 (1276 HK), with a target price of HKD 69.50, indicating a potential upside of 5.3% from the current price of HKD 66.00 [2][3][11]. Core Insights - The company's revenue is expected to grow rapidly in 2025, driven by the continued ramp-up of innovative drug sales and normalized contributions from licensing income. The report highlights that innovative drugs are projected to contribute 58% of total revenue by 2025, with a 26% year-on-year growth in innovative drug sales [2][7]. - Key focus areas for 2026 include the rollout of new products included in the medical insurance list, data readouts from Phase III trials in ADC and weight loss sectors, and the potential for more business development opportunities from a robust early-stage pipeline [2][7]. - The report notes that the current valuation of the company is reasonable, with target prices corresponding to potential upsides of 5% in Hong Kong and 14% in A-shares [2]. Financial Forecasts - The updated financial forecasts for 2026 show expected revenue of RMB 35,377 million, a slight decrease of 0.6% from previous estimates. The gross profit is projected at RMB 30,707 million, with a gross margin of 86.8% [6][14]. - The net profit attributable to shareholders is forecasted to be RMB 8,887 million, reflecting a 1.7% increase from prior estimates, with a net profit margin of 25.1% [6][14]. - The company anticipates a significant increase in innovative drug sales, with a target of over 30% year-on-year growth in 2026, supported by the inclusion of 10 new drugs and 5 new indications in the national medical insurance [7][14].

Investment Rating - The report maintains a Neutral rating for the company [3][7]. Core Views - The company is expected to achieve a revenue growth of 13% in 2025, driven primarily by the continued ramp-up of innovative drug sales and normalized contributions from licensing income [2][7]. - The target price is set at HKD 69.50, indicating a potential upside of 5.3% from the current price of HKD 66.00 [1][7]. Financial Performance Summary - Revenue projections for 2026 are estimated at RMB 35,377 million, a slight decrease of 0.6% from previous forecasts [6]. - Gross profit is expected to be RMB 30,707 million, with a gross margin of 86.8% [6][14]. - Net profit attributable to shareholders is projected at RMB 8,887 million, reflecting a net margin of 25.1% [6][14]. - The company has a strong pipeline with 24 first-class new drugs and 5 second-class new drugs approved for sale in mainland China, with expectations for 53 new products/indications to be approved from 2026 to 2028 [7]. Growth Drivers - Innovative drugs are projected to contribute 58% of total revenue by 2025, with significant growth expected from new products such as 瑞维鲁胺, 达尔西利, and 恒格列净 [2][7]. - The company anticipates a 30% year-on-year growth in innovative drug sales in 2026, supported by new products entering the national medical insurance [7]. - Licensing income is expected to reach RMB 3.39 billion in 2025, with further contributions from collaborations, including a projected USD 250 million from GSK [7]. Valuation Metrics - The company's current valuation is considered reasonable, with target prices reflecting a potential upside of 5% in the Hong Kong market and 14% in the A-share market [2][7]. - The DCF valuation model indicates a per-share value of RMB 63.18 or HKD 69.50 [8].

Summary of Hengrui Medicine Earnings Review Company Overview - **Company**: Hengrui Medicine (600276.SS) - **Industry**: Pharmaceuticals and Biotechnology Key Financial Highlights - **4Q Product Sales**: Rmb7.2 billion, representing a 10% year-over-year increase, aligning with estimates [1] - **Licensing Income**: Rmb1.2 billion recognized in 4Q, exceeding estimates of Rmb661 million, due to a US$100 million booking from the GSK deal [1] - **Earnings**: 4Q earnings rose to Rmb1.96 billion, a 14% year-over-year increase [1] - **Net Profit from Products**: Estimated at Rmb940 million, broadly in line with expectations [1] - **R&D Expenses**: Flat in 4Q, with a higher percentage capitalized, while underlying R&D spending increased by 11% year-over-year [1] Growth Projections - **Innovative Drug Sales Growth**: Management projects a growth target of over 30% for novel drugs in 2026, supported by a strong product cycle [3] - **Key Growth Drivers**: - Trastuzumab rezetecan for HER2+ lung cancer and breast cancer - HR20013 for chemotherapy-induced nausea and vomiting - Multiple chronic disease drugs including vunakizumab, ivarmacitinib, and recaticimab [3] Market Reaction - **Stock Price Reaction**: Following the results announcement, Hengrui's A/H shares declined by -4.57%/-3.31% on March 26th [2] - **Market Consensus**: FY25 revenue forecast of Rmb31.6 billion was below market consensus of Rmb32.8 billion, contributing to weak sentiment [2] Strategic Focus - **Generics Strategy**: Management is cautious on generics, indicating a steady decline, and is optimizing resources towards novel drugs [2] - **Sustainable Licensing Income**: Management highlighted multiple sources for sustainable licensing income, including a growing early-stage pipeline and milestone payments from global partnerships [9] R&D Focus - **Metabolism Pipeline**: Hengrui aims to become a significant player in China's metabolic disease space, with HRS9531 approaching commercialization in 2026 [10] - **Next-Generation Obesity Therapies**: Efforts are being made to address limitations of current GLP-1-based treatments [10] Valuation and Estimates - **Earnings Estimates Revision**: Post-results, earnings estimates were revised up by 8.3% for 2026, reflecting positive expectations on innovative drug sales [11] - **Target Price**: Updated 12-month target price changed to Rmb78.85 from Rmb73.95, based on a long-term exit P/E valuation for generics and a risk-adjusted DCF for innovative drugs [12] Risks - **Key Risks Identified**: - Slower ramp-up of innovative drugs post-NRDL listing - Risk of failure in late-stage R&D programs - Higher-than-expected R&D and administrative expenses for global expansion - Greater-than-expected price cuts for generics and innovative drugs [12]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年3月27日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 会议形式：上证路演中心视频录播和网络互动 问题征集方式：投资者可于 20 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-055 江苏恒瑞医药股份有限公司 关于召开 2025 年年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 一、说明会类型 本次投资者说明会以视频录播结合网络互动形式召开，公司将针对 2025 年 度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露 允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 会议召开时间：2026 年 4 月 7 日下午 15:00-16:00 会议召开地点：上证路演中心 会议内容：恒瑞医药 2025 年年度业绩暨现金分红说明会 会议时间：2026 年 4 月 7 日（星期二）下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频录播和网络互动 三、参加人员 出席本次网络业绩说明会的人员有公 ...

Investment Rating - The report maintains a "Recommended" rating for the company [3]. Core Insights - The company achieved a record high in revenue and profit, with a total revenue of 316.29 billion yuan in 2025, representing a year-on-year growth of 13.02%. The net profit attributable to shareholders reached 77.11 billion yuan, up 21.69% year-on-year [6]. - The sales of innovative drugs significantly contributed to the revenue growth, with innovative drug sales reaching 163.42 billion yuan, a 26.09% increase year-on-year, accounting for 58.34% of total drug sales [6]. - The company is focusing on accelerating the internationalization of its innovative drugs, with licensing income becoming a new growth engine, generating 33.92 billion yuan in revenue during the reporting period [6]. - The report anticipates that the company's net profit attributable to shareholders will grow to 95.19 billion yuan in 2026, reflecting a 23% year-on-year increase, with projected EPS of 1.43 yuan [6][7]. Financial Performance Forecast - Revenue is projected to grow from 31,629 million yuan in 2025 to 38,145 million yuan in 2026, with a growth rate of 20.60% [2]. - The net profit is expected to increase from 7,711 million yuan in 2025 to 9,519 million yuan in 2026, with a growth rate of 23.45% [7]. - The gross margin is forecasted to remain stable, with a slight decrease from 86.21% in 2025 to 85.86% in 2026 [7]. Revenue Breakdown - Innovative drug sales are expected to exceed 30% growth in 2026, driven by strong performance in oncology products and new market entries [6]. - The company’s generic drug revenue has slightly declined due to ongoing impacts from national and local procurement policies, but new products have shown some growth [6]. Valuation Metrics - The report indicates that the current stock price corresponds to a PE ratio of 44 for 2026, 36 for 2027, and 30 for 2028 [6][7].

Summary of the Conference Call for 恒瑞医药 Company Overview - **Company**: 恒瑞医药 (Hengrui Medicine) - **Date of Call**: March 26, 2026 Key Points Industry and Company Insights - **Core Engine of Growth**: By 2025, innovative drug revenue is projected to reach 16.3 billion yuan (+26%), accounting for 58.34% of total revenue. The target for 2026 is to exceed 30% growth, significantly offsetting revenue declines from generic drug procurement policies [2][4] - **Medicare Inclusion**: By the end of 2025, 20 products/indications will be included in Medicare, a significant increase from the beginning of the year. Key products like HER2 ADC, JAK1 inhibitors, and PCSK9 monoclonal antibodies are expected to see rapid growth in 2026 [2] - **Business Development (BD) Normalization**: Since 2023, potential overseas transaction amounts have reached 27 billion USD. A collaboration prepayment with GSK will confirm approximately 250 million USD in 2026, with ongoing milestone payments and sales commissions [2][4] Research and Development Strategy - **Focus on Best-in-Disease**: The R&D strategy emphasizes ADC/AXC, targeted delivery, and small nucleic acid platforms, aiming to overcome challenges in extrahepatic delivery technology. It is expected that 53 new products/indications will be approved between 2026 and 2028 [2][5] - **Differentiated Layout in Metabolic Diseases**: Addressing weight loss quality and compliance issues with GLP-1 drugs, the company is developing APC (antibody-peptide conjugates) and has entered the data focus period for GLP-1/GIP dual-target and oral small molecule drugs for type 2 diabetes [2][6] Financial Performance and Projections - **Decline in Generic Drug Revenue**: The revenue from generic drugs is expected to decline due to national and local procurement policies, with a strategic reduction in investment in certain generic drug varieties. The overall trend is a gradual decrease, as reflected in past financial reports [3][4] - **Projected Revenue Growth**: The innovative drug sales revenue is expected to reach 16.3 billion yuan in 2025, with a 26% year-on-year increase, and the proportion of innovative drugs in total sales is expected to rise [3][4] Product Pipeline and Market Strategy - **Key Products for 2026**: The company anticipates significant growth from products like the HER2 ADC for non-small cell lung cancer and the long-acting PCSK9 monoclonal antibody. The pipeline includes 24 first-class new drugs and 5 second-class new drugs under development [7][8] - **Commercialization Strategy**: The establishment of a biopharmaceutical division aims to drive growth in both oncology and chronic disease sectors. The company is also focusing on grassroots market teams to enhance market penetration [9][10] Collaboration and Internationalization - **BD Collaboration Focus**: The company will continue to emphasize BD collaborations, particularly with late-stage products nearing approval, while also advancing its own overseas clinical trials [12] - **International Market Expansion**: The company is actively pursuing internationalization strategies, including establishing a research center in Boston and exploring the possibility of building sales teams and production bases overseas [12] Clinical Data and Future Outlook - **Upcoming Clinical Data Releases**: In 2026, approximately 25 phase III clinical data readouts are expected, with significant attention on ADC products and key non-oncology projects [13] - **Long-term R&D Goals**: The company plans to push 20 new molecules into clinical stages annually, ensuring robust growth momentum for future pipelines [13] Financial Metrics and Valuation - **Fair Value Changes**: In 2025, the company reported a fair value change income of approximately 25 million USD, primarily driven by equity investments [14] - **RAS Target Pipeline**: The company has established a comprehensive RAS pipeline, with ongoing developments in G12D inhibitors and plans for Pan-RAS inhibitors to address various cancer mutations [15] Small Nucleic Acid Development - **Platform Strategy**: The company is focusing on small nucleic acids, particularly in overcoming challenges in extrahepatic delivery, and plans to increase investment in this area significantly [15] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting the company's focus on innovation, market expansion, and addressing emerging healthcare needs.

Core Viewpoint - Heng Rui Medicine (600276.SH; 01276.HK) reported a continued double-digit growth in its annual performance for 2025, with total revenue reaching 31.629 billion yuan, a year-on-year increase of 13.02%, and a net profit attributable to shareholders of 7.711 billion yuan, up 21.69% [2]. Group 1: Revenue Growth - The growth in performance is primarily driven by the innovative drug segment, which achieved sales revenue of 16.342 billion yuan, a year-on-year increase of 26.09%, accounting for 58.34% of total drug sales revenue [3]. - Within the innovative drug sales, anti-tumor products generated revenue of 13.240 billion yuan, up 18.52%, representing 81.02% of the total innovative drug sales, while non-tumor products reached 3.102 billion yuan, growing by 73.36%, making up 18.98% of the total [3]. Group 2: Product and Market Expansion - In 2025, 20 products/indications of Heng Rui Medicine were included in the updated National Medical Insurance Directory, with 10 products entering the insurance coverage for the first time, leading to significant sales growth for some innovative drugs [4]. - Notable growth was observed in the sales of innovative anti-tumor drugs such as Rivoceranib and Darlisilib, as well as non-tumor products like Empagliflozin and Remimazolam, which benefited from clinical advantages [4]. Group 3: Licensing and Challenges - Revenue from external licensing of innovative drugs reached 3.392 billion yuan in 2025, contributing significantly to the company's overall revenue [4]. - Despite the transition towards innovative drugs, the revenue from the generic drug segment has slightly declined due to domestic centralized procurement policies [4]. - Currently, Heng Rui Medicine has not yet received approval for any innovative drugs in overseas markets but is actively pursuing independent development and registration abroad, with new clinical research centers established in Boston, USA [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年3月26日 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-05 ...